Evidence map›Paper›PMID 35419731›Full record

ArticleJournal of cancer research and clinical oncology2023

Expression of DNA mismatch repair proteins in melanoma patients treated with immune checkpoint inhibitors.

T Gambichler, C Finis, N Abu Rached, C H Scheel, J C Becker, K Lang, H U Käfferlein, T Brüning, N Abolmaali, L Susok

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

T GambichlerSkin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Gudrunstraße, 5644791, Bochum, Germany. t.gambichler@klinikum-bochum.de.ORCID http://orcid.org/0000-0001-7862-3695
C FinisSkin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Gudrunstraße, 5644791, Bochum, Germany.
N Abu RachedSkin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Gudrunstraße, 5644791, Bochum, Germany.
C H ScheelSkin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Gudrunstraße, 5644791, Bochum, Germany.
J C BeckerTranslational Skin Cancer Research, DKTK Partner Site Essen/Düsseldorf, West German Cancer Center, Dermatology, University Duisburg-Essen, Essen, Germany.
K LangInstitute for Prevention and Occupational Medicine of the German Social Accident Insurances, Ruhr-University Bochum (IPA), Bochum, Germany.
H U KäfferleinInstitute for Prevention and Occupational Medicine of the German Social Accident Insurances, Ruhr-University Bochum (IPA), Bochum, Germany.
T BrüningInstitute for Prevention and Occupational Medicine of the German Social Accident Insurances, Ruhr-University Bochum (IPA), Bochum, Germany.
N AbolmaaliInstitute for Diagnostic and Interventional Radiology and Nuclear Medicine, St. Josef Hospital Bochum, Ruhr University Bochum, Bochum, Germany.
L SusokSkin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Gudrunstraße, 5644791, Bochum, Germany.
Ruhr University Bochum · DEInstitute for Prevention and Occupational Medicine · DEGerman Cancer Research Center · DESt. Josef-Hospital · DEUniversity Hospitals of the Ruhr-University of Bochum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the protein expression of DNA mismatch repair (MMR) proteins in patients with cutaneous melanoma (CM) under immune checkpoint inhibitor (ICI) therapy.

methodsImmunohistochemistry was performed on tumor tissue for MMR proteins MLH1, MSH2, MSH6, and PMS2 in 50 metastatic CM patients treated with ICI (ipilimumab, nivolumab, pembrolizumab).

resultsBest overall response (BOR) rate was 48% (24/50). Reduced MMR protein expression (nuclear expression in < 80% of tumor cells) was observed in 8 patients (16%). Compared to other clinical parameters, baseline neutrophil/lymphocyte ratio and reduced intratumoral MMR protein expression (P = 0.0033) were determined as the only parameters significantly associated with favorable BOR. However, in this small study population, reduced MMR protein expression did not reach statistical significance in multivariate analysis.

conclusionReduced MMR protein expression is observed in CM and might predict favorable BOR in patients treated with ICI, as was observed for other entities. However, these findings need to be substantiated in larger patient cohorts.

Indexed as

MelanomaSkin NeoplasmsCutaneous Malignant MelanomaDNA Mismatch RepairHumansImmune Checkpoint InhibitorsMicrosatellite InstabilityMismatch Repair Endonuclease PMS2MutL Protein Homolog 1MutS Homolog 2 ProteinImmune Checkpoint InhibitorsMismatch Repair Endonuclease PMS2MutL Protein Homolog 1MutS Homolog 2 ProteinCutaneous melanomaDNA mismatch repair proteinsImmune checkpoint inhibitorsIpilimumabMicrosatellite instabilityMismatch repair deficiencyNivolumabPembrolizumab

Identifiers

PMID35419731
PMCPMC9984342
OpenAlexW4223930737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.